Russian Journal of Physiotherapy, Balneology and RehabilitationRussian Journal of Physiotherapy, Balneology and Rehabilitation1681-34562413-2969Eco-Vector4134510.17816/41345Research ArticleTHE APPLICATION OF FLUCTUOPHORESIS FOR THE COMBINED TREATMENT OF MODERATE AND SEVERE CHRONIC GENERALIZED PERIODONTITISP’yanzinaAnna Vladimirovnamegakafedra@gmail.ruGerasimenkoMarina Yur’evna-15022013121252823072020Copyright © 2013, Eco-Vector2013The present study included 220 patients aged from 35 to 75 years with the verified diagnosis of moderate and severe chronic generalized periodontitis. It was shown that fluctuophoresis had a positive influence on the clinical and rheographic characteristics and improved the parameters of laser Doppler flowmetry due to the beneficial effect on microcirculation. A course of mildronate fluctuophoresis promoted the improvement of myogenic regulation and nivalin fluctuophoresis normalized neurogenic regulation of the vascular tone. Actovegin fluctuophoresis proved to be sufficiently efficacious as a method for the treatment of the patients with both moderate and severe chronic generalized periodontitis in the absence of the marked prevalence of either myogenic or neurogenic regulation.treatmentchronic generalized periodontitisfluctuophoresisactoveginmildronatenivalinлечениехронический генерализованный пародонтитфлюктуофорезактовегинмилдронатнивалин[Дмитриева Л.А. Пародонтит. М.: Медпресс-информ; 2007.][Кречина Е.К. Мониторинг реактивности микрососудов пародонта с помощью лазерной допплеровской флоуметрии. В кн.: Применение лазерной допплеровской флуометрии в медицинской практике: Материалы 3-го Всероссийского симпозиума. М.; 2000: 133-4.][Ушакова Г.Б. Применение флюктуирующих токов в комплексной терапии пародонтита: Дис.. канд. мед. наук. М.; 1990.][Buchmayer F., Pleiner J., Elmlinger M.W., Lauer G., Nell G., Sitte H.H. Actovegin®: a biological drug for more than 5 decades. Wien. Med. Wochenschr. 2011; 161 (3-4): 80-8.][Jaudzems K., Kuka J., Gutsaits A., Zinovjevs K., Kalvinsh I., Liepinsh E. et al. Inhibition of carnitine acetyltransferase by mildronate, a regulator of energy metabolism. J. Enzyme Inhib. Med. Chem. 2009; 24 (6): 1269-75.][Osborn G.G., Saunders A.V. Current treatments for patients with Alzheimer disease. J. Am. Osteopath. Assoc. 2010; 110 (9, Suppl. 8): 16-26.][Petersen P.E., Ogawa H. Strengthening the prevention of periodontal disease: the WHO approach. J. Periodontol. 2005; 76 (12): 2187-93.][Pupure J., Isajevs S., Skapare E., Rumaks J., Svirskis S., Svirina D. et al. Neuroprotective properties of mildronate, a mitochondria-targeted small molecule. Neurosci. Lett. 2010; 470 (2): 100-5.]